Cancer Letters
Volume 225, Issue 1 , Pages 35-40, 8 July 2005

Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors

  • Linara Axanova

      Affiliations

    • Department of Foods and Nutrition, Purdue University, 700 W. State Street, West Lafayette, IN 47907-205, USA
    • ,
  • D. James Morré

      Affiliations

    • Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 201 S. University Street, West Lafayette, IN 47907-2064, USA
    • ,
  • Dorothy M. Morré

      Affiliations

    • Department of Foods and Nutrition, Purdue University, 700 W. State Street, West Lafayette, IN 47907-205, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 765 494 8233; fax: +1 765 494 0906.

Received 19 August 2004; received in revised form 12 October 2004; accepted 1 November 2004.

Abstract 

An in vitro coculture model of prostate cancer cells (LNCaP) with human osteoblasts (hFOB) was utilized to define the efficacy of the tNOX inhibitors EGCg, capsaicin, Capsibiol-T and phenoxodiol against bone metastasis of prostate cancer alone and in combination with Taxol and cisplatin. In general, the LNCaP cells were more resistant to treatment with EGCg, capsaicin, phenoxodiol and Taxol when grown in coculture than when grown in monoculture. Only with Capsibiol-T (50μM) was growth of LNCaP cells in coculture inhibited comparable with monoculture. Pretreatment with Capsibiol-T followed by the treatment with Taxol had an additive effect on reduction of viability of LNCaP cells in monoculture. In contrast, an antagonistic effect of cisplatin was observed following capsaicin pretreatment.

Keywords: (−)-Epigallocatechin-3-gallate (EGCg), Capsaicin, Phenoxodiol, Capsibiol-T, LNCaP prostate cancer cells, Osteoblasts, Coculture

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(04)00877-8

doi:10.1016/j.canlet.2004.11.017

Cancer Letters
Volume 225, Issue 1 , Pages 35-40, 8 July 2005

Article Tools

* Image Usage & Resolution